GKOS Stock Risk & Deep Value Analysis

Glaukos Corp

DVR Score

8.1

out of 10

Hidden Gem

The Bottom Line on GKOS

We analyzed Glaukos Corp using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran GKOS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 22, 2026•Run Fresh Analysis →

📈GKOS Performance Overview3yr weekly

📊

Unlock GKOS Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

GKOS Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

Medium

Market Risk

Medium

GKOS Deep Value Analysis

Glaukos continues to present a compelling 10x growth thesis driven by the strong commercialization of iDose TR and its dominant position in the MIGS market, evidenced by a robust 35.6% YoY revenue growth in Q4 2025 and a very healthy balance sheet. The expanded TAM and IP moat remain significant advantages. However, the Q4 EPS miss, coupled with significant insider selling and revised down future EPS estimates from analysts, signals increased execution challenges on the path to profitability. This heightens the 'dud validation' risk related to achieving profitability and avoiding dilution, requiring a slight score adjustment to reflect a more cautious outlook on the near-term profitability trajectory despite strong revenue traction. The potential for market leadership is still intact, but the journey may be rockier than previously anticipated.

GKOS Red Flags & Warning Signs

Premium

⚠
Failure to achieve profitability targets or continued EPS misses
⚠
Increased competitive pressures in MIGS or sustained drug delivery
⚠
Slower-than-expected iDose TR adoption or unfavorable reimbursement decisions
⚠
Significant further insider selling

Unlock GKOS Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

GKOS Financial Health Metrics

Market Cap

$5.63B

P/E Ratio

-29.72

Profit Margin

-36.99%

Debt-to-Equity

0.00

Dividend Yield

0.00%

Beta (Volatility)

0.70

Earnings Per Share

$-3.27

GKOS Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

3 Identified

Intangible Assets/IP (patents for MIGS devices and iDose TR)Switching Costs (for physicians and patients adopting novel treatment methods)Efficient Scale (established sales force and distribution network in a specialized market)

Glaukos's moat is durable due to strong intellectual property in both device and drug delivery, which is critical in the heavily regulated medical device and pharmaceutical space. Their focus on interventional ophthalmology creates a specialized market segment where they hold a leadership position. Continued innovation and regulatory approvals will be key to sustaining this.

GKOS Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

GKOS Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q1 2026 Earnings Report (expected late April 2026)
•Continued commercialization and adoption rates of iDose TR
•Updates on reimbursement for iDose TR

Medium-Term (6-18 months)

•Expansion of iDose TR into new international markets
•Pipeline advancements or new product launches in interventional ophthalmology
•Strategic partnerships to accelerate market penetration

Long-Term (18+ months)

•Establishment of iDose TR as standard-of-care for glaucoma management
•Disruption of traditional glaucoma treatment paradigms (daily drops)
•Leadership in next-generation sustained drug delivery platforms

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

GKOS Bull Case: What Could Go Right

✓
Acceleration in iDose TR adoption rates and corresponding revenue growth
✓
Clear path to positive operating cash flow and eventual EPS profitability
✓
Reversal of insider selling trends or new insider buying

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on GKOS

Create a free account to set price alerts and get notified on Telegram when GKOS hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Glaukos Corp (GKOS)?

As of March 22, 2026, Glaukos Corp has a DVR Score of 8.1 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Glaukos Corp?

Glaukos Corp's market capitalization is approximately $5.6B..

What is the risk level for GKOS stock?

Our analysis rates Glaukos Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of GKOS?

Glaukos Corp currently has a price-to-earnings (P/E) ratio of -29.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

Is Glaukos Corp's revenue growing?

Glaukos Corp has reported revenue growth of 32.0%. The company is showing strong top-line momentum.

Is GKOS stock profitable?

Glaukos Corp has a profit margin of -37.0%. The company is currently unprofitable.

How often is the GKOS DVR analysis updated?

Our AI-powered analysis of Glaukos Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 22, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.